Tuesday 3 March 2009 from 09:00 till 18:00 hrs

SESSION 1: OPENING SESSION

• State of the Industry by Mr. Larry Guiheen, PPTA Global Chairman
  
• Role of the reference centers in the treatment of PID by Prof. Alain Fischer , AP-HP Necker Hospital, Paris
  
• Canadian thoughts on self-sufficiency by Dr. Graham Sher, Canadian Blood Service
  

SESSION 2: REGULATORY AFFAIRS - WHAT'S UP IN EUROPE?

• The EMEA Blood Products Working Party: current priorities by Prof. Rainer Seitz, Paul-Ehrlich-Institut
  
• Revision 4 of the guideline on plasma-derived medicinal products by Dr. Johannes Dodt, EMEA
  
• New Variations Regulations by Dr. Martin Terberger, European Commission
  
• Counterfeit medicines - Think locally, act globally by Ms. Bridget Elis, PPTA
  

SESSION 3: RARE DISEASES - A EUROPEAN HEALTH PRIORITY?

• European Commission actions in the field of rare diseases by Mr. Thomas Bregeon, European Commission
  
• The Rare Diseases Community Priorities by Mr. François Houyez, Eurordis
  
• Rare Diseases: The European Parliament's viewpoint, European Parliament
• Plasma related patient organizations by Mr. David Watters, IPOPI
  
• Overview of Member States Public Health Policies for Rare Diseases by Dr. Ségolène Aymé, Orphanet EC TF on Rare Diseases
  

SESSION 4: DEVELOPMENTS IN THE CLINICAL USE OF PLASMA PROTEINS

• New perspectives on the therapeutic use of albumin by Prof. Timothy Evans, The Royal Brompton Hospital, London
  
• Underdiagnosis: the real cost of PID by Mrs. Marcia Boyle, Immune Deficiency Foundation, USA
  
• The role of EAHAD by Prof. Christopher Ludlam, The European Association for Haemophilia and Allied Disorders
  
• Neurological use of Ig review by Prof. Jean-Marc Léger, La Pitié Salpétrière Hospital, Paris
  

Wednesday 4 March 2009 from 08:00 till 16:00 hrs

SESSION 5: MEETING CLINICAL NEEDS - VARIOUS PERSPECTIVES ON HOW MUCH PLASMA WE NEED

• Patient perspective by Mr. Brian O’Mahony, Irish Haemophilia Society
  
• Immunoglobulin: the “driving” product for plasma demand by Dr. Teresa Espanol, Vall d’Hebron Hospital, Barcelona
  
• Ethicist’s perspective by Dr. Jürgen Wallner, University of Vienna
  
• Plasma demand in 2015 by Dr. Patrick Robert, Marketing Research Bureau
  

SESSION 6: GETTING THE PLASMA WE NEED

• Regulatory environment of plasma collection in Germany by Prof. Peter Hellstern, University Hospital Ludwigshafen
  
• Demographic developments by Dr. Sabine Ritter, Robert-Koch-Institut
  
• Sparing the donor’s red cells during frequent plasmapheresis by Dr. Kirsten Seidel, ZLB Plasma
  
• Opening new plasma centers by Mr. Jürgen Wohlfahrt-Laymann, Plasma Service Europe GmbH
  

SESSION 7: OPTIMIZING ACCESS TO PLASMA PROTEIN THERAPIES

• Challenges facing Alpha One Trypsin patients by Mr. Larry Warren, Alpha One
  
• Optimizing access to coagulation factors: patient perspective by Mr. Mark Skinner, World Federation of Hemophilia
  
• Optimizing access to PID treatment: patient perspective by Mrs. Jose Drabwell, IPOPI
  
• The implication of a level playing field by Mr. Jan Bult, PPTA